# A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer

> **NCT01505530** · PHASE2 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 125 (actual)

## Conditions studied

- Pancreatic Cancer

## Interventions

- **DRUG:** LY2495655
- **DRUG:** Placebo
- **DRUG:** Standard of Care Chemotherapy

## Key facts

- **NCT ID:** NCT01505530
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-12
- **Primary completion:** 2014-10
- **Final completion:** 2016-01
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2019-09-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01505530

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01505530, "A Phase 2 Study of LY2495655 in Participants With Pancreatic Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT01505530. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*